VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Vandetanib Advantages in Medullary Thyroid Cancer

Peter Langmuir, MD
Published: Tuesday, Mar 15, 2011

Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer
Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x